This is an observational, multicenter, prospective cohort study including patients treated with CAR-T in Italian centers. Patients eligible for enrollment in the study will be consecutively included in Italian FIL centers. A longitudinal survey will be carried out by collecting patients' data before starting CAR-T (T0) and after 6 (T1), 12 (T2) and 24 (T3) months after CAR-T infusion.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Self-assessed neurocognitive performance
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Neurocognitive performance evaluation: Cognitive Status - Mini-Mental State Examination (MMSE)
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Quality of Life (QoL)
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Psychological status
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Resilience
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Adverse events
Timeframe: The endpoint wil be evaluated at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Treatment characteristics: Previous Central Nervous System Prophylaxis
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy)
Overall Survival (OS)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (at least 24 months after CAR-T infusion)
Neurocognitive performance evaluation: Praxic Abilities - Rey-Osterrieth Complex Figure Test (Copy Condition)
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Neurocognitive performance evaluation: Verbal Memory - Rey Auditory Verbal Learning Test (Word List 3 Recall)
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Neurocognitive performance evaluation: Visual Memory - Rey-Osterrieth Complex Figure Test (Delayed Recall)
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Neurocognitive performance evaluation: Language - Verbal Fluency Test
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Neurocognitive performance status: Attention and Processing Speed - Trail Making Test Part A
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion).
Neurocognitive performance evaluation: Executive Function - Trail Making Test Part B.
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion)
Neurocognitive performance evaluation: Attention and Processing Speed - Symbol Digit Modalities Test (Oral Version)
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion).
Neurocognitive performance evaluation: Executive Function - Frontal Assessment Battery
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy), at 6, 12 and 24 months after CAR-T infusion (from the beginning of the study at least 24 months after CAR-T infusion).
Treatment characteristics: Cumulative Anthracycline Dose
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy).
Treatment characteristics: Prior Radiotherapy Field
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy).
Treatment characteristics: Prior Radiotherapy Dose
Timeframe: The endpoint wil be evaluated at screening (before starting CAR-T therapy).